This Article Full Text Full Text (PDF) All Versions of this Article: 146/4/1718    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Størling, J. Articles by Mandrup-Poulsen, T. Search for Related Content PubMed PubMed Citation Articles by Størling, J. Articles by Mandrup-Poulsen, T.

Antitumorigenic Effect of Proteasome Inhibitors on Insulinoma Cells

Laboratory for ß-Cell Biology (J.S., A.E.K., N.B., T.M.-P.), Steno Diabetes Center, Gentofte 2820, Denmark; Division of Medical Genetics (N.A.-P., C.B.), Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland; and Rolf Luft Center for Diabetes Research (T.M.-P.), Department of Molecular Medicine, Karolinska Institute, S-176 76 Stockholm, Sweden

Address all correspondence to: Thomas Mandrup-Poulsen, M.D., DMSc, Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark. E-mail: tmpo{at}steno.dk. Address reprint requests to: Joachim Størling, MSc, Steno Diabetes Center, Niels Steensens Vej 2, DK-2820 Gentofte, Denmark. E-mail: jstq{at}steno.dk.

Malignant insulinoma is a critical cancer form with a poor prognosis. Because cure by surgery is infrequent, effective chemotherapy is in demand. Induction of cell death in tumor cells by proteasome inhibitors is emerging as a potential strategy in cancer therapy. Here we investigated whether inhibition of the proteasome has an antitumorigenic potential in insulinoma cells. Exposure of mouse ßTC3 insulinoma cells to the proteasome inhibitor N-Acetyl-Leu-Leu-Nle-CHO (ALLN) reduced cell viability, activated caspase-3, induced apoptosis, and suppressed insulin release. Treatment with ALLN also resulted in phosphorylation of c-jun N-terminal kinase (JNK) and an increase in in vitro phosphorylation of c-jun. In insulinoma cells with impaired JNK signaling, ALLN-induced apoptosis was significantly suppressed. Another proteasome inhibitor, lactacystin, also stimulated JNK activation, caused activation of caspase-3, suppressed cell viability, and induced apoptosis in ßTC3 and rat INS-1E cells. Both ALLN and lactacystin caused a marked decrease in the cellular amount of the JNK scaffold protein JNK-interacting protein 1/islet-brain-1. In primary pancreatic rat islet cells, proteasome inhibition reduced insulin secretion but had no impact on cell viability and even partially protected against the toxic effect of proinflammatory cytokines. Our findings demonstrate that proteasome inhibitors possess antitumorigenic and antiinsulinogenic effects on insulinoma cells.

This article has been cited by other articles:

				S. Casas, R. Gomis, F. M. Gribble, J. Altirriba, S. Knuutila, and A. Novials Impairment of the Ubiquitin-Proteasome Pathway Is a Downstream Endoplasmic Reticulum Stress Response Induced by Extracellular Human Islet Amyloid Polypeptide and Contributes to Pancreatic {beta}-Cell Apoptosis Diabetes, September 1, 2007; 56(9): 2284 - 2294. [Abstract] [Full Text] [PDF]